S Gail Eckhardt, MD

Associate Dean of Cancer Programs; Director of the LIVESTRONG Cancer Institute; Department Chair; Professor

1991 …2018
If you made any changes in Pure, your changes will be visible here soon.

Personal profile


S. Gail Eckhardt is the inaugural director of the LIVESTRONG Cancer Institutes of the Dell Medical School. She is overseeing the creation of a transdisciplinary cancer research program at The University of Texas at Austin, one that will lead to new models of prevention, treatment and patient-centered cancer care, and new models of teaching and training future doctors.

Eckhardt came to Dell Medical School from the University of Colorado Denver’s Anschutz Medical Campus, where she led the Division of Medical Oncology for eight years.

She graduated from the University of Texas Medical Branch in Galveston and, before moving to Colorado, served as associate director of clinical research at the Cancer Therapy and Research Center’s Institute for Drug Development in San Antonio.

Eckhardt conducted her internship and residency in internal medicine at the University of Virginia Medical School. She completed a postdoctoral research fellowship in experimental and molecular medicine at Scripps Research Institute and a fellowship in medical oncology at the University of California, San Diego.

Eckhardt has served in national leadership roles including the American Society of Clinical Oncology (ASCO) Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee and the National Cancer Institute (NCI) Cancer Centers Study Section. She is a member of the NCI Investigational Drug Steering Committee and the NCI Colorectal Cancer Task Force, and she serves on seven external advisory boards of NCI-designated cancer centers.

Eckhardt is the principal investigator on studies involving early clinical trials and colorectal cancer research. She has conducted numerous phase I and II clinical trials and has published more than 177 manuscripts.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 6 Similar Profiles
Neoplasms Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences
Heterografts Medicine & Life Sciences
docetaxel Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1991 2018

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer

Klauck, P. J., Bagby, S. M., Capasso, A., Bradshaw-Pierce, E. L., Selby, H. M., Spreafico, A., Tentler, J. J., Tan, A. C., Kim, J., Arcaroli, J. J., Purkey, A., Messersmith, W. A., Kuida, K., Eckhardt, S. G. & Pitts, T. M., Feb 5 2018, In : BMC Cancer. 18, 1, 136.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Cell Line
Inhibitory Concentration 50
1 Citations

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L. & Munster, P., Jul 1 2018, In : Annals of Oncology. 29, 7, p. 1561-1568 8 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Adenoid Cystic Carcinoma

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer

Davis, S. L., Eckhardt, S. G., Diamond, J. R., Messersmith, W. A., Dasari, A., Weekes, C. D., Lieu, C. H., Kane, M., Choon Tan, A., Pitts, T. M. & Leong, S., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Somatomedin Receptors
Insulin Receptor

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Diamond, J. R., Eckhardt, S. G., Pitts, T. M., van Bokhoven, A., Aisner, D., Gustafson, D. L., Capasso, A., Sams, S., Kabos, P., Zolman, K., Colvin, T., Elias, A. D., Storniolo, A. M., Schneider, B. P., Gao, D., Tentler, J. J., Borges, V. F. & Miller, K. D., Aug 2 2018, In : Breast Cancer Research. 20, 1, 82.

Research output: Contribution to journalArticle

Aurora Kinases
Triple Negative Breast Neoplasms
Phase II Clinical Trials
Angiogenesis Inhibitors
1 Citations

Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms

Scott, A. J., Arcaroli, J. J., Bagby, S. M., Yahn, R., Huber, K. M., Serkova, N. J., Nguyen, A., Kim, J., Thorburn, A., Vogel, J., Quackenbush, K. S., Capasso, A., Schreiber, A., Blatchford, P., Klauck, P. J., Pitts, T. M., Eckhardt, S. G. & Messersmith, W. A., Oct 1 2018, In : Molecular Cancer Therapeutics. 17, 10, p. 2112-2122 11 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms